Abstract 5822
Background
The real life experience in clinical arena can be challenging for student nurses, to cope with the patients’ suffering, to provide care, to communicate with them and their caregivers as death approaches .It is essential to understand student nurses’ feelings when confronted a dying patient, so that specific training, consultation and empowerment give them prior to their clinical placement. However, there has been little research in Greece on student nurses’ experience when facing care of patients and their caregivers in the last days of life.The purpose of this study was to explore undergraduate student nurse’s experience facing death and dying of a patient during their clinical practice.
Methods
A qualitative, descriptive design was used. Qualitative data were collected in June 2018 from 4th -year nursing students’ of Nursing School of National and Kapodistrian University of Athens. Experiences were collected through written reflections to obtain data about their experience when cared for a serious ill patient and when delivered their care to a dying patient and their caregivers. A content analysis of their comments was carried out.
Results
From 101 undergraduated nurses 42 answered in open-ended question “Please describe the death experience of a patient during your clinical practice”. The response rate was 41,6%.The average age of the students was 22.Nursing students’ comments revealed concerns on handling the family/caregivers of the dying patient, their willingness to care for body of the dying, expressing their emotions such as sadness, describing death experience using medical terminology and using their previous personal experiences and knowledge to handle with . Thus five categories were emerged, the concept of “family/caregivers issues” “participation in the care of the dying” “description of the event using medical terminology”, “expressing emotions positive or negative” and “referring to their previous experience and knowledge” respectively.
Conclusions
Study’s findings highlighted the influence of knowledge, personal attitudes and clinical stressors that student nurses faced in a clinical practice when they were training in palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract